These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17686105)

  • 1. Assessment of combined symptom and medication scores for rhinoconjunctivitis immunotherapy clinical trials.
    Clark J; Schall R
    Allergy; 2007 Sep; 62(9):1023-8. PubMed ID: 17686105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The average Adjusted Symptom Score, a new primary efficacy end-point for specific allergen immunotherapy trials.
    Grouin JM; Vicaut E; Jean-Alphonse S; Demoly P; Wahn U; Didier A; de Beaumont O; Montagut A; Le Gall M; Devillier P
    Clin Exp Allergy; 2011 Sep; 41(9):1282-8. PubMed ID: 21375606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.
    Rolinck-Werninghaus C; Wolf H; Liebke C; Baars JC; Lange J; Kopp MV; Hammermann J; Leupold W; Bartels P; Gruebl A; Bauer CP; Schnitker J; Wahn U; Niggemann B
    Allergy; 2004 Dec; 59(12):1285-93. PubMed ID: 15507097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
    Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W
    Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
    Didier A; Malling HJ; Worm M; Horak F; Sussman G; Melac M; Soulié S; Zeldin RK
    Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy.
    Didier A; Melac M; Montagut A; Lhéritier-Barrand M; Tabar A; Worm M
    Allergy; 2009 Jan; 64(1):166-71. PubMed ID: 19076546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
    Valovirta E; Jacobsen L; Ljørring C; Koivikko A; Savolainen J
    Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
    Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
    J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.
    Bufe A; Eberle P; Franke-Beckmann E; Funck J; Kimmig M; Klimek L; Knecht R; Stephan V; Tholstrup B; Weisshaar C; Kaiser F
    J Allergy Clin Immunol; 2009 Jan; 123(1):167-173.e7. PubMed ID: 19130937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
    Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
    Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
    Dahl R; Stender A; Rak S
    Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sublingual immunotherapy in youngsters: adherence in a randomized clinical trial.
    Röder E; Berger MY; de Groot H; Gerth van Wijk R
    Clin Exp Allergy; 2008 Oct; 38(10):1659-67. PubMed ID: 18631346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
    Roberts G; Hurley C; Turcanu V; Lack G
    J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients.
    Howarth P; Malling HJ; Molimard M; Devillier P
    Allergy; 2012 Mar; 67(3):321-7. PubMed ID: 22142377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis.
    Worm M
    Eur Ann Allergy Clin Immunol; 2006 Dec; 38(10):355-60. PubMed ID: 17274520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule.
    Colás C; Monzón S; Venturini M; Lezaun A
    J Allergy Clin Immunol; 2006 Apr; 117(4):810-6. PubMed ID: 16630938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double-blind, placebo-controlled study.
    Mirone C; Albert F; Tosi A; Mocchetti F; Mosca S; Giorgino M; Pecora S; Parmiani S; Ortolani C
    Clin Exp Allergy; 2004 Sep; 34(9):1408-14. PubMed ID: 15347374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of short-term immunotherapy using molecular standardized grass and rye allergens compared with symptomatic drug treatment on rhinoconjunctivitis symptoms, skin sensitivity, and specific nasal reactivity.
    Klimek L; Mewes T; Wolf H; Hansen I; Schnitker J; Mann WJ
    Otolaryngol Head Neck Surg; 2005 Oct; 133(4):538-43. PubMed ID: 16213926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage.
    Durham SR; Riis B
    Allergy; 2007 Aug; 62(8):954-7. PubMed ID: 17620075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.